Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$4.17 USD
-0.12 (-2.80%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $4.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Corvus Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CRVS 4.17 -0.12(-2.80%)
Will CRVS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVS
Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
CRVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CRVS
Corvus Pharmaceuticals Q2 2025 Earnings Preview
Corvus Pharmaceuticals (CRVS) Gains China Approval for Soquelitinib Trial | CRVS Stock News
Corvus announces IND application approved by CDE of China NMPA to start trial
Corvus announces IND application approved by CDE of China NMPA to start trial
Mizuho Securities Remains a Buy on Corvus Pharmaceuticals (CRVS)